Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer Science

• Publication date

  2008-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1349-7006.2008.00945.xPMID 19016767PMCID PMC11159082
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular Targeting and Treatment of Composite EGFR and EGFRvIII-Positive Gliomas Using Boronated Monoclonal Antibodies

  2008cited by this paper
• Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines

  2007cited by this paper
• Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor

  2007cited by this paper
• Visualizing the dynamics of EGFR activity and antiglioma therapies in vivo.

  2007cited by this paper
• Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface.

  2007cited by this paper
• Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII.

  2007cited by this paper
• EGFR-targeting monoclonal antibodies in head and neck cancer.

  2006cited by this paper
• Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.

  2006cited by this paper
• Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption.

  2006cited by this paper
• EGFR-targeting monoclonal antibodies in head and neck cancer.

  2006cited by this paper
• Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor–Specific Antibody Generates Enhanced Antitumor Activity

  2005cited by this paper
• Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.

  2005cited by this paper
• Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

  2005cited by this paper
• Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.

  2005cited by this paper
• Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab Augments Radiation Effects in Glioblastoma Multiforme in Vitro and in Vivo

  2005cited by this paper
• An epidermal growth factor receptor chimeric human-murine monoclonal antibody

  2005cited by this paper
• Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme

  2004cited by this paper
• Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR)

  2004cited by this paper
• Monoclonal antibodies as therapeutic agents for cancer.

  2004cited by this paper
• Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225)

  2004cited by this paper
• Epidermal growth factor receptor tyrosine kinase inhibitors

  2004cited by this paper
• Targeting of cells expressing wild‐type EGFR and type‐III mutant EGFR (EGFRvIII) by anti‐EGFR MAb ICR62: A two‐pronged attack for tumour therapy

  2003cited by this paper
• Enhanced Anti‐tumor Effect of Trastuzumab in Combination with Cisplatin

  2002cited by this paper
• Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody C225 against Glioblastoma Multiforme

  2002cited by this paper
• Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha.

  2002cited by this paper
• Epidermal growth factor receptor tyrosine kinase inhibitors.

  2002cited by this paper
• Monoclonal antibodies to target epidermal growth factor receptor–positive tumors

  2002cited by this paper
• Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.

  2001cited by this paper
• Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

  2000cited by this paper
• Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors.

  2000cited by this paper
• The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling*

  1997cited by this paper
• Crohn's disease and ulcerative colitis Surgical management

  1996cited by this paper
• A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis.

  1996cited by this paper
• Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene.

  1995cited by this paper
• Molecular pathways in the formation of gliomas

  1995cited by this paper
• Malignant Brain Tumors

  1995cited by this paper
• A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.

  1994cited by this paper
• Structural alterations of the epidermal growth factor receptor gene in human gliomas.

  1992cited by this paper
• Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas.

  1990cited by this paper
• Epidermal growth factor

  1972cited by this paper

• Nanosystems at Nexus: Navigating Nose-to-Brain Delivery for Glioblastoma Treatment.

  2025cites this paper
• Alternative Splicing-Mediated Resistance to Antibody-Based Therapies: Mechanisms and Emerging Therapeutic Strategies

  2025cites this paper
• Inhibition of EGFR/ErbB does not protect against C. difficile toxin B

  2024cites this paper
• Insights into Targeted and Stimulus‐Responsive Nanocarriers for Brain Cancer Treatment

  2024cites this paper
• AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy.

  2024cites this paper
• Exploring Novel Therapeutic Opportunities for Glioblastoma Using Patient-Derived Cell Cultures

  2023cites this paper
• Advances in antibody-based drugs and their delivery through the blood-brain barrier for targeted therapy and immunotherapy of gliomas.

  2023cites this paper
• The War Is on: The Immune System against Glioblastoma—How Can NK Cells Drive This Battle?

  2022cites this paper
• Refining the delivery and therapeutic efficacy of cetuximab using focused ultrasound in a mouse model of glioblastoma: an 89Zr-cetuximab immunoPET study.

  2022cites this paper
• Quantum dots: The cutting-edge nanotheranostics in brain cancer management.

  2022cites this paper
• Drug Conjugates for Targeting Eph Receptors in Glioblastoma

  2020cites this paper
• Overcoming the Blood–Brain Barrier: Successes and Challenges in Developing Nanoparticle-Mediated Drug Delivery Systems for the Treatment of Brain Tumours

  2020cites this paper
• Therapeutic Efficacy of GC1118, a Novel Anti-EGFR Antibody, against Glioblastoma with High EGFR Amplification in Patient-Derived Xenografts

  2020cites this paper
• Personalized and translational approach for malignant brain tumors in the era of precision medicine: the strategic contribution of an experienced neurosurgery laboratory in a modern neurosurgery and neuro-oncology department.

  2020cites this paper
• Modulating chitosan-PLGA nanoparticle properties to design a co-delivery platform for glioblastoma therapy intended for nose-to-brain route

  2020cites this paper
• A novel strategy for glioblastoma treatment combining alpha-cyano-4-hydroxycinnamic acid with cetuximab using nanotechnology-based delivery systems

  2020cites this paper
• Alternative Splicing: Expanding the Landscape of Cancer Biomarkers and Therapeutics

  2020cites this paper
• Potential roads for reaching the summit: an overview on target therapies for high-grade gliomas

  2020cites this paper
• Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma.

  2019cites this paper
• EGFRvIII: An Oncogene with Ambiguous Role

  2019cites this paper
• Receptor-Targeted Glial Brain Tumor Therapies

  2018cites this paper
• Gene Therapy, and Immunotherapy in Malignant Gliomas

  2018cites this paper
• EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise

  2017cites this paper
• A rational approach to enhancing antibody Fc homodimer formation for robust production of antibody mixture in a single cell line.

  2017influential citation
• Role of key genetic mutations on increasing migration of brain cancer cells through confinement

  2017cites this paper
• A rational approach to enhancing antibody Fc homodimer formation for robust production of antibody mixture in a single cell line

  2017influential citation
• Endovascular therapies for malignant gliomas: Challenges and the future.

  2016cites this paper
• Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities.

  2016cites this paper
• Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer

  2015cites this paper
• Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles

  2015cites this paper
• Glioblastoma multiforme: Pathogenesis and treatment.

  2015cites this paper
• Identifikation von Resistenzmechanismen gegenüber EGFR-Tyrosinkinase Inhibitoren in EGFR-amplifizierten und EGFRvIII-positiven Glioblastomen

  2015cites this paper
• Monoclonal Antibody–Conjugated Superparamagnetic Iron Oxide Nanoparticles for Imaging of Epidermal Growth Factor Receptor–Targeted Cells and Gliomas

  2015cites this paper
• Monoclonal antibody-conjugated superparamagnetic iron oxide nanoparticles for imaging of epidermal growth factor receptor-targeted cells and gliomas.

  2015cites this paper
• A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma.

  2015cites this paper
• Integrated Systems and Technologies Apoptosis Imaging for Monitoring DR 5 Antibody Accumulation and Pharmacodynamics in Brain Tumors Noninvasively

  2014cites this paper
• Glioblastoma multiforme: State of the art and future therapeutics

  2014cites this paper
• Enhanced Anti-Tumor Effect of Zoledronic Acid Combined with Temozolomide against Human Malignant Glioma Cell Expressing O6-Methylguanine DNA Methyltransferase

  2014cites this paper
• BRAF overexpression induces rampant glioma proliferation independent of phospho-EGFR expression.

  2014cites this paper
• Apoptosis imaging for monitoring DR5 antibody accumulation and pharmacodynamics in brain tumors noninvasively.

  2014cites this paper
• Epithelial Membrane Protein-2 (EMP2) Activates Src Protein and Is a Novel Therapeutic Target for Glioblastoma*

  2014cites this paper
• Anti-Angiogenesis, Gene Therapy, and Immunotherapy in Malignant Gliomas

  2014cites this paper
• KRAS mutation confers resistance to antibody‐dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells

  2014cites this paper
• Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma

  2013cites this paper
• Dominant Negative Epidermal Growth Factor Receptor Inhibits Growth of Human Gastric Cancer Cells by Inducing Cell Cycle Arrest and Apoptosis

  2013cites this paper
• Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.

  2013cites this paper
• Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.

  2013cites this paper
• Mechanisms of Aggressiveness in Glioblastoma: Prognostic and Potential Therapeutic Insights

  2013cites this paper
• The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered

  2013cites this paper
• Synthesis and purification of a toxin-linked conjugate targeting epidermal growth factor receptor in Escherichia coli.

  2012cites this paper
• Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy.

  2012influential citation
• Novel mechanisms of cytokine signaling on T-cell and MDSC function in glioma development

  2012cites this paper
• Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions

  2012cites this paper
• Cetuximab induces mitochondrial translocalization of EGFRvIII, but not EGFR: involvement of mitochondria in tumor drug resistance?

  2012cites this paper
• Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3

  2011cites this paper
• Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism

  2011cites this paper
• In silico studies on marine actinomycetes as potential inhibitors for Glioblastoma multiforme

  2011cites this paper
• Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor.

  2011cites this paper
• Experimental approaches for the treatment of malignant gliomas.

  2010cites this paper
• Therapeutic targeting of EGFR in malignant gliomas

  2010cites this paper
• Cetuximab Insufficiently Inhibits Glioma Cell Growth Due to Persistent EGFR Downstream Signaling

  2010cites this paper
• Epidermal growth factor receptor inhibitors: current status and future directions.

  2009cites this paper
• The role of the chemokine receptor CXCR4 in EGFRvIII-expressing breast cancer

  2009cites this paper
• Immunotherapeutic approaches for glioma.

  2009cites this paper
• Targeted Therapy of Glioblastoma Stem-like Cells and Tumor Non- Stem Cells Using Cetuximab-conjugated Iron-oxide Nanoparticles the Epidermal Growth Factor Receptor (egfr) Is Frequently Overexpressed in the Most Common Malignant Glioma, Glioblastoma (gbm), and Represents an Important Therapeutic Targ

  year unknowncites this paper